209 related articles for article (PubMed ID: 24125838)
21. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
23. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
[TBL] [Abstract][Full Text] [Related]
24. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
Gómez-Casares MT; García-Alegria E; López-Jorge CE; Ferrándiz N; Blanco R; Alvarez S; Vaqué JP; Bretones G; Caraballo JM; Sánchez-Bailón P; Delgado MD; Martín-Perez J; Cigudosa JC; León J
Oncogene; 2013 Apr; 32(17):2239-46. PubMed ID: 22710719
[TBL] [Abstract][Full Text] [Related]
25. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
26. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
27. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
[TBL] [Abstract][Full Text] [Related]
28. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
[TBL] [Abstract][Full Text] [Related]
29. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
30. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
Cilloni D; Messa F; Arruga F; Defilippi I; Morotti A; Messa E; Carturan S; Giugliano E; Pautasso M; Bracco E; Rosso V; Sen A; Martinelli G; Baccarani M; Saglio G
Leukemia; 2006 Jan; 20(1):61-7. PubMed ID: 16270044
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
Gamas P; Marchetti S; Puissant A; Grosso S; Jacquel A; Colosetti P; Pasquet JM; Mahon FX; Cassuto JP; Auberger P
Leukemia; 2009 Aug; 23(8):1500-6. PubMed ID: 19340007
[TBL] [Abstract][Full Text] [Related]
33. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
[TBL] [Abstract][Full Text] [Related]
34. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
Dong Y; Xiong M; Duan L; Liu Z; Niu T; Luo Y; Wu X; Xu C; Lu C
Apoptosis; 2014 Aug; 19(8):1281-92. PubMed ID: 24830786
[TBL] [Abstract][Full Text] [Related]
35. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
36. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
Baran Y; Salas A; Senkal CE; Gunduz U; Bielawski J; Obeid LM; Ogretmen B
J Biol Chem; 2007 Apr; 282(15):10922-34. PubMed ID: 17303574
[TBL] [Abstract][Full Text] [Related]
37. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
40. Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling.
Yan J; Li QF; Wang LS; Wang H; Xiao FJ; Yang YF; Wu CT
Anticancer Drugs; 2012 Jan; 23(1):22-31. PubMed ID: 21857502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
